Cargando…

Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial

Chronic pruritus persists for > 6 weeks and is known to decrease patients’ quality of life. Due to the complex pathological mechanism of chronic pruritus, there is still a lack of satisfactory therapeutic agents; therefore, complementary therapies are required to improve itching symptoms. In the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Jung-Hee, Jun, Purumea, Park, Gunhyuk, Kwon, Ojin, Choi, Yujin, Lim, Hye-Sun, Moon, Byeong Cheol, Kim, Kyuseok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678534/
https://www.ncbi.nlm.nih.gov/pubmed/36401407
http://dx.doi.org/10.1097/MD.0000000000031470
_version_ 1784834007284842496
author Jang, Jung-Hee
Jun, Purumea
Park, Gunhyuk
Kwon, Ojin
Choi, Yujin
Lim, Hye-Sun
Moon, Byeong Cheol
Kim, Kyuseok
author_facet Jang, Jung-Hee
Jun, Purumea
Park, Gunhyuk
Kwon, Ojin
Choi, Yujin
Lim, Hye-Sun
Moon, Byeong Cheol
Kim, Kyuseok
author_sort Jang, Jung-Hee
collection PubMed
description Chronic pruritus persists for > 6 weeks and is known to decrease patients’ quality of life. Due to the complex pathological mechanism of chronic pruritus, there is still a lack of satisfactory therapeutic agents; therefore, complementary therapies are required to improve itching symptoms. In the Republic of Korea, Sopoongsan, an herbal formula, has been used to treat itching, dizziness, and skin paralysis. To our knowledge, this is the first study to evaluate whether Sopoongsan improves chronic pruritus and to identify Sopoongsan-related changes in the immune response in patients with chronic upper body pruritus. METHODS: A randomized, double-blind, placebo-controlled parallel trial will be conducted to assess 20 patients with chronic upper body pruritus for 3 months who have been diagnosed with allergic atopic dermatitis or seborrheic dermatitis. The patients will be randomly allocated to either the placebo-control (n = 10) or treatment (n = 10) group. The total study period will be 8 weeks (i.e., administration of Sopoongsan or placebo drugs for 4 wk and follow-up for 4 wk). Participants will be allowed to receive external treatment, except for antipruritic medications administered orally, throughout the study period. The primary outcome measure will be the numeric rating scale results for itching, whereas the secondary outcome measures will be questionnaire survey (Dermatological Life Quality Index and Epworth Sleepiness Scale) findings and the immune response index, including interferon gamma, interleukin-4, immunoglobulin E, thymic stromal lymphopoietic protein, and histamine, to investigate the biological mechanisms underlying chronic pruritus. DISCUSSION AND CONCLUSIONS: We expect that the results of this study will provide important clinical evidence regarding the effectiveness of Sopoongsan on itching symptoms, quality of life, sleep disturbance, and changes in the immune response. The findings will help elucidate the mechanism underlying the therapeutic effect of Sopoongsan for chronic pruritus and lay the foundation for further studies in this area.
format Online
Article
Text
id pubmed-9678534
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96785342022-11-22 Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial Jang, Jung-Hee Jun, Purumea Park, Gunhyuk Kwon, Ojin Choi, Yujin Lim, Hye-Sun Moon, Byeong Cheol Kim, Kyuseok Medicine (Baltimore) 3800 Chronic pruritus persists for > 6 weeks and is known to decrease patients’ quality of life. Due to the complex pathological mechanism of chronic pruritus, there is still a lack of satisfactory therapeutic agents; therefore, complementary therapies are required to improve itching symptoms. In the Republic of Korea, Sopoongsan, an herbal formula, has been used to treat itching, dizziness, and skin paralysis. To our knowledge, this is the first study to evaluate whether Sopoongsan improves chronic pruritus and to identify Sopoongsan-related changes in the immune response in patients with chronic upper body pruritus. METHODS: A randomized, double-blind, placebo-controlled parallel trial will be conducted to assess 20 patients with chronic upper body pruritus for 3 months who have been diagnosed with allergic atopic dermatitis or seborrheic dermatitis. The patients will be randomly allocated to either the placebo-control (n = 10) or treatment (n = 10) group. The total study period will be 8 weeks (i.e., administration of Sopoongsan or placebo drugs for 4 wk and follow-up for 4 wk). Participants will be allowed to receive external treatment, except for antipruritic medications administered orally, throughout the study period. The primary outcome measure will be the numeric rating scale results for itching, whereas the secondary outcome measures will be questionnaire survey (Dermatological Life Quality Index and Epworth Sleepiness Scale) findings and the immune response index, including interferon gamma, interleukin-4, immunoglobulin E, thymic stromal lymphopoietic protein, and histamine, to investigate the biological mechanisms underlying chronic pruritus. DISCUSSION AND CONCLUSIONS: We expect that the results of this study will provide important clinical evidence regarding the effectiveness of Sopoongsan on itching symptoms, quality of life, sleep disturbance, and changes in the immune response. The findings will help elucidate the mechanism underlying the therapeutic effect of Sopoongsan for chronic pruritus and lay the foundation for further studies in this area. Lippincott Williams & Wilkins 2022-11-18 /pmc/articles/PMC9678534/ /pubmed/36401407 http://dx.doi.org/10.1097/MD.0000000000031470 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3800
Jang, Jung-Hee
Jun, Purumea
Park, Gunhyuk
Kwon, Ojin
Choi, Yujin
Lim, Hye-Sun
Moon, Byeong Cheol
Kim, Kyuseok
Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial
title Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial
title_full Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial
title_fullStr Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial
title_full_unstemmed Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial
title_short Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial
title_sort effectiveness of sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: a pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678534/
https://www.ncbi.nlm.nih.gov/pubmed/36401407
http://dx.doi.org/10.1097/MD.0000000000031470
work_keys_str_mv AT jangjunghee effectivenessofsopoongsanforchronicupperbodypruritusinpatientswithatopicorseborrheicdermatitisapilotstudyprotocolforarandomizeddoubleblindplacebocontrolledparalleltrial
AT junpurumea effectivenessofsopoongsanforchronicupperbodypruritusinpatientswithatopicorseborrheicdermatitisapilotstudyprotocolforarandomizeddoubleblindplacebocontrolledparalleltrial
AT parkgunhyuk effectivenessofsopoongsanforchronicupperbodypruritusinpatientswithatopicorseborrheicdermatitisapilotstudyprotocolforarandomizeddoubleblindplacebocontrolledparalleltrial
AT kwonojin effectivenessofsopoongsanforchronicupperbodypruritusinpatientswithatopicorseborrheicdermatitisapilotstudyprotocolforarandomizeddoubleblindplacebocontrolledparalleltrial
AT choiyujin effectivenessofsopoongsanforchronicupperbodypruritusinpatientswithatopicorseborrheicdermatitisapilotstudyprotocolforarandomizeddoubleblindplacebocontrolledparalleltrial
AT limhyesun effectivenessofsopoongsanforchronicupperbodypruritusinpatientswithatopicorseborrheicdermatitisapilotstudyprotocolforarandomizeddoubleblindplacebocontrolledparalleltrial
AT moonbyeongcheol effectivenessofsopoongsanforchronicupperbodypruritusinpatientswithatopicorseborrheicdermatitisapilotstudyprotocolforarandomizeddoubleblindplacebocontrolledparalleltrial
AT kimkyuseok effectivenessofsopoongsanforchronicupperbodypruritusinpatientswithatopicorseborrheicdermatitisapilotstudyprotocolforarandomizeddoubleblindplacebocontrolledparalleltrial